Imaging features associated with survival outcomes among colorectal cancer patients with and without KRAS mutation

Promsorn, Julaluck; Chadbunchachai, Payia; Somsap, Kulyada; Paonariang, Krisada; Sa-ngaimwibool, Prakasit; Apivatanasiri, Chaiwat; Lahoud, Rita Maria; Harisinghani, Mukesh G.

doi:10.1186/s43055-020-00393-x

Cited by 3 publications

(1 citation statement)

References 61 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study with approximately the same number of patients as those in our study (N=113) and with a similar result is the one conducted by Promsorn and colleagues, where it was demonstrated that there were no significant differences in OS between patients with KRAS mutations and those without (p=0.159) but with the mention that those in the KRAS mutation group had a lower SR [12]. A similar result was obtained by the research of Habashy et al, in which OS did not differ significantly between patients with wild-type and mutant KRAS [13].…”

Section: Discussionsupporting

confidence: 87%

Genetic Profiling and Survival Outcomes in Romanian Colorectal Cancer Patients

Vesa,

Maghiar,

Pop

et al. 2024

Cureus

View full text Add to dashboard Cite

Background: The increasing incidence of colorectal cancer is one of the most frequently addressed medical topics worldwide. It represents the third most commonly diagnosed cancer in both men and women globally, with significant implications for public health. Mortality for this type of malignancy remains high, second only to lung cancer. Given their clinical relevance, the identification and understanding of KRAS and BRAF mutations have become crucial components of personalized medicine approaches in colorectal cancer. Hence, our desire is to carry out a research that analyzes the impact of these mutations in terms of survival and mortality on patients diagnosed with colorectal cancer. Methods: We conducted a retrospective study spanning from 2018 to 2022, which involved 118 patients diagnosed with colorectal cancer. The patients were selected from the databases of the Oradea County Emergency Clinical Hospital and Pelican Oradea Hospital. Genetic testing was performed at the "Resident Laboratory" clinic. Subsequently, patients were divided into two groups of equal size based on the presence or absence of mutations. Results: The survival rate one year after the diagnosis of colorectal cancer is 84.74% (N=50/59) for the mutant group versus 67.96% (N=40/59) for the wild-type group. The survival rate at five years from the diagnosis of colorectal cancer is 25.93% (N=15/59) for patients with wild-type tumors compared to 33.54% (N=20/59) for patients with tumors with mutant status (p=0.483, HR=1.153, CI 95% 0.7661-1.735). The five-year survival rate, depending on the mutation present, highlights the fact that the average overall survival for those with the KRAS mutation is 38.6 months (CI 95% 35.22-41.97) and for those with the BRAF mutation is 8.3 months (CI 95% 5.42-11.17) (p=0.039). The mortality rate for mutant KRAS is 44.89% (N=22/50), while for those with mutant BRAF, it is 100% (N=6/6). Conclusions: We observed no statistically significant difference in overall survival rate and disease-free interval between the two studied groups, but the overall survival was better for those with mutations present (38.64 months versus 31.07 months for wild-type tumors). The mortality rate is higher among tumors with wild-type status (p=0.005), in the first year after the diagnosis of colorectal cancer. The BRAF mutation confers a much worse prognosis than the KRAS mutation, from both the survival analysis and the mortality rate.

show abstract

Section: Discussionsupporting

confidence: 87%